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Abstract: Previously, we engineered oncolytic herpes simplex viruses (o-HSVs) retargeted to the
HER2 (epidermal growth factor receptor 2) tumor cell specific receptor by the insertion of a single
chain antibody (scFv) to HER2 in gD, gH, or gB. Here, the insertion of scFvs to three additional cancer
targets—EGFR (epidermal growth factor receptor), EGFRvIII, and PSMA (prostate specific membrane
antigen)—in gD ∆6–38 enabled the generation of specifically retargeted o-HSVs. Viable recombinants
resulted from the insertion of an scFv in place of aa 6–38, but not in place of aa 61–218. Hence,
only the gD N-terminus accepted all tested scFv inserts. Additionally, the insertion of mIL12 in the
US1-US2 intergenic region of the HER2- or EGFRvIII-retargeted o-HSVs, and the further insertion of
Gaussia Luciferase, gave rise to viable recombinants capable of secreting the cytokine and the reporter.
Lastly, we engineered two known mutations in gB; they increased the ability of an HER2-retargeted
recombinant to spread among murine cells. Altogether, current data show that the o-HSV carrying the
aa 6–38 deletion in gD serves as a platform for the specific retargeting of o-HSV tropism to a number
of human cancer targets, and the retargeted o-HSVs serve as simultaneous vectors for two molecules.
Keywords: retargeting; oncolytic herpesvirus; PSMA; EGFR; EGFRvIII; mIL12; Gaussia Luciferase; HER2
1. Introduction
Oncolytic virotherapy and immunotherapy represent a novel frontier in cancer treatment.
The therapeutic viruses can be combined with standard of care or novel treatments, including check
point inhibitors, for front-line or second-line treatments [1–6]. A variety of viruses are being evaluated
as anti-cancer agents in clinical trials. In a few cases, the wild type (wt) or naturally occurring
mutant forms were employed. In most cases, genetic modifications were introduced in order to
confer cancer specificity [7–11]. Genetically engineered and mutant forms of herpes simplex virus
(HSV) stand as effective or as highly promising agents because of a number of features, including the
ample genome (150 kbp) capable of accepting the insertion of heterologous genes, and the detailed
knowledge of the properties of the viral genes, with respect to virus biology and pathogenesis (reviewed
in [7]). The oncolytic HSV (o-HSV) named OncovexGM-CSF (granulocyte monocyte-colony stimulating
factor) or T-VEC (Talimogene laherparepvec, commercial name Imlygic), approved for the therapy of
metastatic melanoma by the Food and Drug Administration and European Medicines Agency [12–17],
and the o-HSVs in clinical trials gain cancer specificity from genetic modifications or natural mutations
which attenuate virulence and replication to varying degrees [18–22]. Not all these mutants are
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highly effective, and there is a need for o-HSVs which replicate robustly in cancer cells and are highly
cancer specific. To meet these needs, we and others designed non-attenuated o-HSVs retargeted to
cancer specific receptors of choice, exemplified by IL13Rα2 (Interleukin 13 receptor α2), HER2 (human
epidermal growth factor receptor 2), EGFR (epidermal growth factor receptor), and uPAR (urokinase
plasminogen activator receptor) [23–29]. The retargeted viruses carry no genomic modifications other
than those required for the tropism retargeting; hence, they are fully virulent.
The first-generation retargeted o-HSVs carry the retargeting ligand in gD, in place of a portion
of the glycoprotein. The deleted sequence is critical for gD interaction with the natural receptors
HVEM (herpesvirus entry mediator) and nectin1. The resulting recombinants are detargeted from
these receptors [30]. In our laboratory, the selected cancer target was human HER2 and the retargeting
moiety was a high-affinity scFv. The HER2-retargeted viruses named R-LM113 and R-LM249 carry
the deletion of aa 6–38 or of aa 61–218, respectively [27,28]. They exhibit safety and efficacy in
preclinical models of immunosuppressed or immunocompetent mice. The routes of administration
have been intra-tumoral, intra-peritoneal, or systemic via carrier cells [28,31–34]. Glorioso and Grandi
selected EGFR for the successful design of retargeted HSVs optimized for glioblastoma therapy [29].
Recently, we demonstrated that gH or gB, two additional glycoproteins essential for HSV entry,
can also serve as retargeting tools [35,36]. The availability of alternative retargeting strategies led to the
construction of a non-cancer cell line for the in vitro cultivation of retargeted o-HSV [37]. In particular,
the recombinants carrying the scFv to HER2 in gD and the GCN4 peptide in gB, gH, or gD infected and
replicated in a Vero cell line derivative named Vero-GCN4R, which transgenically expresses an artificial
receptor to GCN4, named GCN4R [37–39]. The double-retargeted recombinants alternatively infect the
HER2-positive cancer cells via HER2, and the producer Vero-GCN4R cell line via the GCN4-GCN4R
interaction. Additional strategies to attain cancer specificity include transcriptional retargeting [40]
and retargeting through miRNAs differentially expressed in healthy or tumor tissue [41], exploiting the
pathway of miRNAs which are abundantly expressed or induced across the herpesviridae family [42].
The aims of this work were threefold: (i) to ascertain whether we could generate o-HSVs retargeted
to tumor cell specific receptors other than HER2 by using the backbones of R-LM113 or of R-LM249.
The selected targets were EGFR, in its wt form or variant III form (EGFRvIII), and the prostate specific
membrane antigen (PSMA), expressed in a variety of cancers, in glioblastoma and in prostate cancers,
respectively; (ii) to identify additional sites in the HSV genome for the insertion of heterologous
genes, exemplified by the interleukin 12 (IL12) cytokine, and to test the simultaneous expression of the
novel reporter Gaussia Luciferase (GLuc), suitable for viral detection in vitro and in vivo; and (iii) to
investigate whether two previously described mutations in gB result in o-HSVs with enhanced spread
in murine cells.
2. Materials and Methods
2.1. Cells and Viruses
We employed an array of different cell lines, taking into account the different receptor usage of the
retargeted recombinant viruses. SK-OV-3 (human ovary adenocarcinoma), LNCaP (human prostate
adenocarcinoma), and RS (rabbit skin) were obtained from ATCC. R6, a cell line expressing HSV gD
in an inducible manner, was described in [43]. Rh4 rhabdomyosarcoma cells were described in [44].
U251 MG cells (human glioma, for simplicity designated as “U251” in this paper) were received from
Dr. Bernard Roizman (University of Chicago). hGic-G7 and hGic-G15, human glioma initiating cells
from glioblastoma patients, were described in [45]. MDA-MB-231 cells (EGFR positive mammary
gland/breast metastatic adenocarcinoma), were received from Dr. Pier-Luigi Lollini (University of
Bologna). CHO-EGFR cells were received from Dr. Steve Russell (Mayo Clinic, Rochester, MN,
USA) [46]. TRAMP-PSMA and PC3-PIP-PSMA cells were received from Dr. Marco Colombatti and
Dr. Giulio Fracasso (University of Verona). J cells, resistant to HSV infection, and J-nectin1, expressing
the single human receptor nectin1, were described in [47]. J-HER2 cells were described in [26].
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Here, J cells expressing EGFR, EGFRvIII, or PSMA were generated by transfection of the plasmids
described below (see Section 2.2). U251-EGFRvIII cells were generated by plasmid transfection and
cell cloning, while B16-HER2 cells (mouse melanoma) were generated by transduction with a lentiviral
vector [48]. The expression of heterologous receptors in cell lines was checked by flow cytometry.
Recombinant BACs and viruses described in this paper are listed in Table 1; the cell lines used for their
characterization are listed in Table 2. The cell lines employed for virus titrations are listed in Table 3.
HSV-1(F) is the wt prototype [49]. R-LM5 carries loxP-bracketed pBeloBAC11 (which includes
BAC sequences) between UL3 and UL4 [50] and the reporter EGFP gene engineered in pBeloBac11.
It is the wt-gD counterpart of the HSV recombinants [27]. R-LM113 and R-LM249 carry an scFv to
HER2 in gD ∆6–38 or gD ∆61–218, respectively, in addition to the BAC sequences inserted between
UL3 and UL4, as in R-LM5 [27,28]. The key features of viruses are listed in Table 1. Virus stocks were
prepared by infecting cell monolayers in T175 flasks with virus seeds at a multiplicity of infection
(MOI) of 0.5 PFU/cell and harvesting at 48 h. Infected cells were scraped and pelleted at 300× g.
Pellets were sonicated for 10 s on ice, and frozen at −80 ◦C in 50 µL aliquots to avoid repeated
freeze-thaw cycles. One aliquot for each virus stock was thawed to determine the titer in the cell
lines listed in Table 3. For titrations, cells were infected with serially diluted virus stocks. After 1.5 h
absorption, the monolayers were overlaid with medium containing agarose (1% Seaplaque Agarose).
Plaques were counted at day 3.
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Table 1. Key features of wt and recombinant (R) viruses, of recombinant viral genomes (BAC), and of the parental viruses employed in this paper.
Recombinant
Virus * Derived From
RETARGETING ADDITIONAL MODIFICATIONS
Ref.
Insertion of scFv to ** Insertion in Genetic Modification *** Site of Insertion Purpose
R-593 PSMA gD ∆6–38 This paper
R-611 EGFR gD ∆6–38 This paper
R-613 EGFRvIII gD ∆6–38 This paper
R-615 R-613 EGFRvIII gD ∆6–38 mIL12 **** US1-US2 immunotherapy This paper
R-613GLuc R-613 EGFRvIII gD ∆6–38 GLuc **** UL37-UL38 luciferase secretion This paper





R-LM113 HER2 gD ∆6–38 [27]
R-115 R-LM113 HER2 gD ∆6–38 mIL12 US1-US2 immunotherapy This paper
R-LM249 HER2 gD ∆61–218 [28]
R-291 R-LM249 HER2 gD ∆61–218 D285N + A549T in gB UL27 (gB) enhanced infectionor spread This paper
Recombinant
viral genome *
BAC-591 PSMA gD ∆61–218 This paper
BAC-621 EGFR gD ∆61–218 This paper




HSV-1(F) Nectin1, HVEM [49]





All the recombinants derive from a backbone carrying pBeloBAC11 and EGFP inserted between UL3 and UL4 [27,50]. * Prefix R- denotes recombinant virus; prefix BAC denotes
recombinant viral genome, as BAC-DNA. ** Size of inserts ranges between 747 and 801 bp, including flanking serine-glycine linkers upstream and/or downstream the scFv. *** Size of
inserts: 1326 bp (GLuc cassette), 3200 bp (mIL12 cassette). **** mIL12 (murine interleukin 12); GLuc (Gaussia Luciferase).
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Table 2. Cell lines employed for the characterization of the recombinant viruses and BACs.
Cell Line Infecting RecombinantVirus Displayed Receptor Genetic Modification Tissue/Cell Type Ref.
Human cancer
LNCaP R-593, R-LM5 Natural HSV receptors *, PSMA none hu prostate adenocarcinoma [51]
MDA-MB-231 R-LM5, R-611 Natural HSV receptors *, EGFR none hu mammary adenocarcinoma [52]
hGic-G7 R-LM5 Natural HSV receptors * none hu glioblastoma [45]
hGic-G15 R-613, R-LM5 Natural HSV receptors *, EGFRvIII none hu glioblastoma [45]
PC3-PIP-PSMA R-593 Natural HSV receptors *, PSMA express hu PSMA hu prostate adenocarcinoma [53]
Rh4 R-LM5 Natural HSV receptors * none hu muscle rhabdomyosarcoma [44]
SK-OV-3 R-LM5, R-LM113, R-115,R-LM249, R-291, R-611
Natural HSV receptors *, HER2,
EGFR none hu ovary adenocarcinoma [54]
U251** R-LM5 Natural HSV receptors *, EGFR none hu glioma [55]
U251-EGFRvIII R-613, R-615, R-613GLuc,R-615GLuc, R-LM5
Natural HSV receptors *, EGFR,
EGFRvIII express hu EGFRvIII hu glioma This paper
Animal cell lines
B16-HER2 R-LM249, R-291 HER2 express hu HER2 mu melanoma [48]
CHO-EGFR R-611 EGFR express hu EGFR hamster ovary [46]
J none none wt HSV receptor negative hamster kidney [47]
J-EGFR R-611 EGFR express hu EGFR hamster kidney This paper
J-EGFRvIII R-613, R-615, R-613GLuc,R-615GLuc EGFRvIII express hu EGFRvIII hamster kidney This paper
J-HER2 R-LM113, R-115, R-LM249,R-291 HER2 express hu HER2 hamster kidney [27]
J-nectin1 R-LM5 Nectin1 express hu nectin1 hamster kidney [47]
J-PSMA R-593 PSMA express hu PSMA hamster kidney This paper
RS R-611, R-LM5 not characterized*** none rabbit skin
R6 BAC-591, BAC-621, BAC-623,R-593, R-611, R-613 not characterized*** inducible HSV gD rabbit skin [43]
TRAMP-PSMA R-593 PSMA express hu PSMA mu prostate epithelium [56]
* Nectin1, HVEM/HveA; ** U251MG: for simplicity “U251” throughout the paper; *** can be inferred from range of infection.
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Table 3. Cell lines employed for titration of the viruses used in this paper.
Cell line Employed for Titration Virus
SK-OV-3 HSV-1(F), R-LM5, R-LM113, R-115, R-LM249, R-291, R-611
J-PSMA R-593
U251-EGFRvIII R-613, R-615, R-613GLuc, R-615GLuc
2.2. Plasmids
The following plasmids were generated, or obtained from other laboratories, in order to engineer
cell lines expressing cancer-specific receptors. pIRES-PSMA was obtained from Angelo Baccala,
Cleveland Clinic. pcDNA-EGFR I (isoform “a”), the cDNA encoding EGFR, was amplified with primers
T7 and BGHrev using the DNA from CHO-EGFR cells as a template. The amplicon was cut with XbaI
and HindIII and cloned in pcDNA3.1(-). The plasmid pCDNA-EGFRvIII was engineered by performing
a deletion in the pcDNA-EGFR I isoform “a” insert, with primers BGHrev and Xba_EGFRvIII_f (TGT
GCT CTA GAT GCG ACC CTC CGG GAC GGC CGG GGC AGC GCT CCT GGC GCT GCT GGC
TGC GCT CTG CCC GGC GAG TCG GGC TCT GGA GGA AAA GAA AGG TAA TTA TGT GGT
GAC AGA TCA CGG). The latter is a chimeric primer including the XbaI site, the sequence encoding
the signal peptide and the first five amino acids of mature EGFR, the GGT triplet (encoding the
“scar” glycine resulting from the deletion of exons 2 to 7), and 23 nt annealing to the sequence
encoding amino acids 274–280. As above, the amplicon was cut with XbaI and HindIII and cloned
in pcDNA3.1(-). The inserts were sequenced for accuracy. Single chain antibodies (scFv) inserts:
pSL1180-scFv-PSMA encoding J591 scFv directed to PSMA was obtained from Dr. Michel Sadelain,
Memorial Sloan-Kettering Cancer Center; anti-EGFR scFv, cloned in pTNHaa-EGFR, was obtained
from Dr. Steve Russell, Mayo Clinic [46]; and anti-EGFRvIII scFv (cloned in plasmid pMR1ENV1),
was obtained from Dr. Ian Lorimer, Ottawa Health Research Institute [57]. The plasmids were used
as a template to amplify the respective scFvs, which were subsequently inserted in the appropriate
recombinant HSV genome by means of galK recombineering [35,58]. The primers employed for
amplification are listed in Table 4.
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Table 4. Templates and primers for the second step of galK recombineering.
Recombinant Template Forward Primer Reverse Primer
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The mIL12 expression cassette was assembled in several steps. First of all, the ORF of mIL12b
(subunit b) from clone IMAGE 40046200 was cloned in pcDNA3.1(-) downstream of a synthetic
Kozak sequence with primers mIL12b_f (CAG ACC AGG CAG GCG GCC GCA CGC CAC CAT
GTG TCC TCA GAA GCT AAC CAT CTC) and mIL12b_Eco_r (AAC GTT GAA TTC TAG GAT
CGG ACC CTG CAG GGA), generating the pLM82 plasmid. Next, the ORF of mIL12a (subunit
a) was inserted downstream of mIL12b ORF, following amplification from clone IMAGE 40126170
with primers mIL12a_Bam_f (TGC CGG ATC CGC ATG TGT CAA TCA CGC TAC CTC CTC) and
mIL12a_Hind_r (AGG GCC TTG AAG CTT TCA GGC GGA GCT CAG ATA GCC C), generating the
pLM83 plasmid. To ensure the expression of both subunits, an IRES sequence was amplified from
pIRESneo with primers IRES_Eco_f (GTC TAG AAT TCA TTT TCC ACC ATA TTG CCG TCT TTT
GG) and IRES_Bam_r (TAT TGG ATC CAG GAA TTA TCC CGG GGT TGT GGC AAG C), and cloned
between the two mIL12 subunits, thus generating the final plasmid pLM84. pCMV-GLuc2 containing
the copepod Gaussia princeps Luciferase under the control of the pCMV promoter was obtained from
New England Biolabs. Plasmid gB_D285N_A549T cl 2 was generated by a site directed mutagenesis
kit of the gB ORF cloned in pcDNA3.1(-), by means of QuickChangeII XL Stratagene with primer
gB_D285N_EcoRI_f (GCT CGG TGT ACC CGT ACA ACG AAT TCG TGC TGG CGA CTG GC) and its
complement, and primer gB_A549T_NheI_f (GCA AGC TGA ACC CCA ACA CGA TCG CTA GCG
CCA CCG TGG GCC GGC GGG) and its complement.
2.3. Engineering of the Recombinant HSVs
The recombinant viral DNAs containing the BAC sequences, and generated by genetic engineering
in bacteria, are hereafter designated as “BAC”, followed by the appropriate number. The recombinant
viruses are designated with the letter “R”, followed by the appropriate number. To exemplify, when
the recombinant BAC-593 is transfected into appropriate cells, it generates the corresponding HSV-1
recombinant named R-593.
2.3.1. Structure of the HSV Backbone
HSV BAC genomes were engineered by galK recombineering [35,58]. In the intergenic UL3 and
UL4 region, all the recombinant genomes carry the loxP-bracketed pBeloBac11, which includes the
BAC sequences [50], and the reporter EGFP gene [27,28]. Glycoprotein D carries either the deletion
of amino acids 6–38 or 61–218. Some derivatives were further modified to express mIL12 or Gaussia
Luciferase (GLuc). The main characteristics of the recombinants are summarized in Table 1. Table 4
summarizes the templates and primers used to generate each construct. Specific modifications for
retargeting purposes were as follows. The recombinants containing the scFvs in place of aa 6–38 were
R-593 (scFv to PSMA), R-613 (scFv to EGFRvIII), and R-611 (scFv to EGFR). Downstream of the scFvs,
we inserted linker L3 (SSGGGSGSGGS). The BACs containing the scFvs in place of aa 61–218 were
BAC-591 (scFv to PSMA), BAC-623 (scFv to EGFRvIII), and BAC-621 (scFv to EGFR); the scFv was
flanked by upstream linker L1 (HSSGGGSG) and by downstream linker L2 (SSGGGSGSGGSG).
2.3.2. Mutagenesis of gB
BAC-LM249 was the starting genome to generate BAC-291, which carries the mutations
D285N and A549T in gB [59]. A fragment encompassing the mutations was used to perform galK
recombineering in gB ORF (Table 4).
2.3.3. Insertion of mIL12 Cassette
As a site of insertion for mIL12, we chose the intergenic region between US1 and US2. The insertion
was in the middle of the US1-US2 intergenic region, at coordinate 133854 (HSV-1 strain F, GenBank #
GU734771.1), 84 bp downstream of the US1 ORF stop codon.
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2.3.4. Production of Recombinant Viruses
Recombinant viruses were reconstituted by transfection of the purified BAC genome in
mammalian cells (R6) and subsequently amplified in cell lines expressing the appropriate target
receptor: R-593 in J-PSMA and R-613 in J-EGFRvIII or U251-EGFRvIII. R-611 was initially reconstituted
in CHO-EGFR, and then passaged in RS or in SK-OV-3 cells. The same approach was applied to
BAC-591, BAC-623, and BAC-621, but it did not yield a recombinant virus able to replicate in cells
expressing the cognate target receptor.
2.4. Viral Tropism
Cell monolayers were exposed to the recombinant viruses at MOI ranging from 2 to 10 PFU/cell.
Infection was monitored through EGFP by fluorescence microscopy. Flow cytometry (BD Accuri
C6) was used to measure EGFP or the binding of MAb 52S to gH (see Supplementary Materials).
Neutralization of infection by cetuximab (Merck) was assayed by incubating cells with 83 µg/mL
cetuximab 1 h before, during (1.5 h), and after (24 h) exposure to the virus.
2.5. Virus Growth
Cells seeded in 12-well plates were infected at 0.1 or 1 PFU/cell. After 90 min of virus adsorption,
the inoculum was removed and the unpenetrated virus was inactivated by an acid wash (40 mM citric
acid, 10 mM KCl, 135 mM NaCl, pH 3) [60] and cultures were frozen at 24, 48, or 72 h after infection.
The progeny virus (intracellular plus extracellular) was titrated in a receptor-positive cell line (see
Table 3), as detailed above in Section 2.1. The effect of cetuximab (Merck) on virus growth was assayed
as described in Section 2.4; samples were collected at 24 and 48 h and titrated in receptor-positive
cells. Data were plotted as the average of at least two independent experiments ± SD, as detailed in
Figure legends.
2.6. Viral Spread Assay
Cells were infected with serially diluted virus stocks. After 1.5 h of adsorption, the monolayers
were covered with an agarose overlay (1% Seaplaque Agarose). Infection and plaque formation were
monitored over three days. For plaque size measurement, 35 pictures of plaques for each sample were
taken with a Nikon DS-Vi1 camera, connected to a Nikon fluorescence microscope, and equipped
with a 4× objective. Plaque area in pixels was measured with the ImageJ “Measure” tool and used to
perform a statistical analysis (T-Test, two-tailed, Significance Level: 0.05).
2.7. Cytotoxicity Assay
Cells in 96 well plates (8·103 cells/well) were infected at the indicated MOI or mock-infected.
AlamarBlue (10 µL/well, Life Technologies, Carlsbad, CA, USA) was added to the culture media at
two to eight days after infection. Four hours later, plates were read with a GloMax Discover System
(Promega, Madison, WI, USA) or with an EnSpire Multimode Plate Reader (PerkinElmer, Waltham,
MA, USA), according to the manufacturer’s instructions. Cell viability was expressed as the percentage
difference in alamarBlue reduction in infected relative to uninfected cells. Samples were run at least in
triplicate and the results were plotted as average ± SD.
2.8. ELISA for mIL12
Cells were seeded in 48-well plates and infected with recombinant viruses. The concentration of
mIL12 secreted in the medium was measured with the Mouse IL12 (p70) ELISA Plate kit (ThermoFisher
Scientific Pierce, Waltham, MA, USA), according to the manufacturer’s instructions. Absorbance was
read with a GloMax Discover System (Promega) at 450 and 560 nm.
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2.9. GLuc Assay
The luminescence activity of GLuc secreted by cells infected with recombinant viruses was determined
by incubating 25 µL of the cell medium (diluted 1:3 in DMEM) with 50 µL of Dual-Glo Stop & Glo Substrate
(Promega), shaking for 5 s, and reading with a GloMax Discover System (Promega) with 1 s of integration
time. Gaussia Luciferase activity is plotted as RLU after normalization to the background of the viral
inoculum. The graphs represent the average of three independent experiments ± SD.
3. Results
3.1. Construction of Cell Lines Expressing the Targeted Receptors PSMA, EGFRvIII and EGFR
In order to analyze the tropism of the recombinants described in this study, we generated a
number of cell lines expressing a single heterologous tumor cell specific receptor. Thus, J cells negative
for HSV-1 natural receptors [47], were engineered to express PSMA, EGFR, or EGFRvIII. The expression
of the targeted receptors was checked by flow cytometry (Figure 1A–C). EGFRvIII was transgenically
expressed in the human glioma cell line U251, thus generating U251-EGFRvIII (Figure 1D). Of note,
the double peak in pane l D accounts for the expression of wt EGFR in U251, as shown in Figure 1H.
The mouse melanoma cell line B16 was engineered to express HER2 (Figure 1E). The reactivity of the
MAb to EGFR on J and J-nectin1 cell lines documents the expression of a rodent ortholog of EGFR
(Figure 1F,G).
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Figure 1. Expression of the indicated receptors in the cell lines generated and employed in this study.
Already available cell lines are included for comparison. Cells were reacted with monoclonal antibodies
to PSMA (A, red line), EGFR (B–H, green line), or HER2 (E, blue line). MAb to EGFR is reactive to both
EGFR and EGFRvIII. Black lines represent the background signal of the secondary antibody alone.
3.2. The PSMA-Retargeted R-593
R-593 was designed to target the prostate tumor cell specific receptor PSMA [61]. It was
engineered by insertion of the anti-PSMA scFv in gD in place of aa 6–38, and therefore carries
the same deletion in gD as R-LM113 (the schematic diagram of R-593 genome and the linear map
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of wt and R-593 gD are shown in Figure 2A,B). The aa 6–38 deletion in gD ablates targeting and
binding to nectin1 and HVEM [27]. The key features of R-593 are summarized in Table 1. In this and
previous work, for retargeting assays, we preferentially employed J cells, a derivative of BHK-TK cells,
resistant to HSV infection and defective in the expression of the natural HSV receptors [47], and a
number of its derivatives transgenically expressing a single receptor of choice [26–28]. To exemplify,
J-nectin1, J-HER2, and J-PSMA enable the infection of wt-HSV-1, the HER2-retargeted o-HSVs, or the
PSMA-retargeted R-593, respectively. We also included R-LM5, a recombinant which carries the BAC
sequences and the EGFP reporter in the UL3-UL4 intergenic region, and wt-gD [27], which is the
wt counterpart of the recombinants (summary of properties in Table 1). Infection was monitored by
fluorescence microscopy (Figure 2C), taking advantage of the EGFP reporter engineered in R-593,
and was quantified by flow cytometry as EGFP fluorescence (Figure 2D), or by indirect fluorescence
with MAb 52S to gH (Supplementary Table in Supplementary Materials). Figure 2C, panel a, and
2D, panel a, show that R-593 efficiently infected J-PSMA cells (97.5% by flow cytometry) and failed
to infect J-nectin1 cells (Figure 2C, panel d; 0.1% infection by flow cytometry in Figure 2D, panel b).
In contrast to R-593, R-LM5 efficiently infected J-nectin1 cells (Figure 2C, panel e, and Figure 2D, panel
b; 86.5% by flow cytometry), and caused infection of J-PSMA cells only in a few cells in the monolayer
(Figure 2C, panel b; 0.4% by flow cytometry, Figure 2D, panel a). Virus yield experiments showed that
R-593 replicated to yields of 106 PFU/mL in J-PSMA cells, and to yields of 102 PFU/mL in J-nectin1
cells, corresponding to one progeny virion per about 1000 cells. Conversely, HSV-1(F) and R-LM5
replicated to yields of 106 PFU/mL or higher in J-nectin1 cells, and to yields of 102 PFU/mL in J-PSMA
cells. The latter figure is consistent with the extent of EGFP detection in Figure 2C, panels b. Together,
the tropism and the virus growth experiments in Figure 2C–E support the conclusion that R-593 was
retargeted to PSMA and detargeted from the natural receptor nectin1, as expected, because of the aa
6–38 deletion in gD. We consider the few infected cells seen in Figure 2C, panel b, the flow cytometry
extent of infection below 5%, and the yields around 102–103 PFU/mL as negligible background here
and in subsequent experiments. It may be consequent to the so called unconventional infection of
HSV-1 in J cells [59,62].
With respect to growth in cancer cell lines, R-593 replicated in PC3-PIP-PSMA, a cell line derived
from a human prostate adenocarcinoma made transgenic for PSMA, to a titer similar to that attained
in J-PSMA (Figure 2E). Replication in the murine prostate cancer TRAMP-PSMA was about two
orders of magnitude lower (Figure 2E), a result in agreement with the scarce infection of murine
cells, in particular cells derived from C57BL/6 mice, which are among the most highly resistant
to HSV [63–65]. The cytotoxic activity of R-593 was specific for PSMA expressing cells, and was
undetectable in J-nectin1 cells (Figure 2F). Conversely, HSV-1(F) exerted no cytotoxic effect in J-PSMA
cells, which express PSMA as the sole receptor, but was cytotoxic in J-nectin1, as expected (Figure 2F).
Of note, R-593 readily infected LNCaP cells, a human prostate cancer cell line, which naturally
expresses PSMA (Figure 2G), implying that the extent of PSMA expression in human cancer cells
makes them a target for R-593 infection and virotherapy. These results indicate that it is possible
to specifically retarget the HSV tropism to the human PSMA prostate tumor cell specific receptor
by engineering an scFv to PSMA in gD, in place of the 6–38 aa sequences, which are critical for the
interaction with the gD receptors HVEM and nectin1.
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repeat (IR) sequences are represented as rectangular boxes. The scFv to PSMA is inserted in gD, in place
of aa 6–38. pBeloBAC11 and EGFP (BAC EGFP) are inserted between UL3 and UL4 [50]. (B) Schematic
linear maps of R-593 gD, and of wt gD. The aa coordina es releva t to this study are ndicated. The two
linear maps are drawn to scale. Scale bar, 50 amino acid residues. Note that the size of R-593 gD is
almost doubled relative to that of wt gD, as a consequence of scFv insertion. L3, linker 3. (C) J-PSMA or
J-nectin1 cell lines were infected with th indicated viruses at 10 PFU/cell. Pictures were taken at 24 h
p.i. The levels, brightness, and contrast of the panels ere adjusted by means of Adobe Photoshop as
follows: input level (black) 30, brightness +60, contrast +60, scale bar =100 µm. (D) J-PSMA or J-nectin1
cells exposed to 10 PFU/cell of R-593 or R-LM5 or mock infected (black line); at 24 h after infection,
the infected cells were analyzed for EGFP fluorescence by flow cytometry. The figures next to each
virus name indicate the percentage of infected cells. Vertical red line: threshold discriminating the
negative and positive populations, as determined by comparison with the negative control. (E) R-593
replication in J-PSMA, J-nectin1, or the PSMA-expressing prostate murine (TRAMP-PSMA) or human
(PC3-PIP-PSMA) tumor cell lines. Cells were infected at 0.1 PFU/cell, and harvested at 24 or 48 h after
infection. The plotted values represent the average of three independent experiments (for J-PSMA and
J-nectin1) or two independent experiments for TRAMP-PSMA and PC3-PIP-PSMA, ± SD. (F) Effect
of virus infection on viability of J-PSMA (solid lines) or J-nectin1 (dashed lines) cells, infected at
2.5 PFU/cell. The data represent the average of four replicate samples ± SD. (G) R-593 infection of the
human prostate cancer cell line LNCaP detected by fluorescence microscopy (panel a). Panel b shows
the extent of infection as detected by flow cytometry. Vertical red line: threshold between negative and
positive populations, scale bar = 100 µm.
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3.3. The EGFRvIII-Retargeted R-613
The R-613 recombinant was designed to target EGFRvIII, a glioma-specific variant of EGFR
which carries a 26 amino acid deletion in the extracellular domain [66–68]. R-613 was engineered
by insertion of the anti-EGFRvIII scFv in gD in place of aa 6–38, and therefore carries the same
deletion in gD as R-LM113 (the schematic diagram of the R-613 genome and the linear map of wt
and R-613 gD are shown in Figure 3A,B). The key features of R-613 are summarized in Table 1.
Given that EGFRvIII is a glioma-specific receptor, for tropism and virus growth assays, we made use
of a human EGFRvIII-negative glioma cell line (U251), in which we transgenically expressed EGFRvIII
(U251-EGFRvIII). The tropism assay showed that R-613 selectively infected U251-EGFRvIII but not
wt U251 cells, as seen by fluorescence microscopy (Figure 3C, panels a and d) and quantified by
flow cytometry (Figure 3D; 99.3% and 2.3% infection in U251-EGFRvIII and U251 cells, respectively).
Thus, R-613 was retargeted to EGFRvIII and detargeted from nectin1. R-613 replicated efficiently in
U251-EGFRvIII cells, and reached yields similar to those attained by R-LM5 (Figure 3E). In agreement
with the virus growth and tropism assays, R-613 exhibited cytotoxic activity in U251-EGFRvIII cells
(Figure 3F), but not in U251 cells (Figure 3G). To ascertain whether R-613 was capable of infecting
human glioma cells, we employed cultures of human glioma initiating cells (hGic), also known as
glioma stem cells, from glioblastoma patients [45]. By real time RT-PCR, the extent of EGFRvIII
expression was quantified to be at least 250 fold higher in hGic-G15 than in hGic-G7, where it was
undetectable over 40 PCR cycles; hence hGic-G7 and hGic-G15 were considered to be negative and
positive for EGFRvIII, respectively (Figure S1 in Supplementary Materials). As shown in Figure 3H,
hGic-G15 cells were infected with R-613 (panels a, b), whereas hGic-G7 cells were not (panels c,
d). Cumulatively, the data indicate that for specific retargeting, the 6–38 aa sequences of gD can be
successfully substituted with an scFv to EGFRvIII receptor, and that the extent of EGFRvIII expression
in human glioma initiating cells makes the latter a target for R-613 infection and virotherapy.
3.4. The EGFR-Retargeted R-611
R-611 was designed to target EGFR, a receptor overexpressed and/or amplified in a variety of
cancers, their metastases, and also widely expressed in non-cancer cells [69–71]. R-611 was engineered
by insertion of the anti-EGFR scFv in gD, in place of aa 6–38, and therefore carries the same deletion in
gD as R-LM113 (see Figure 4A,B for a schematic diagram of the R-611 genome and the linear map of
wt and R-611 gD). The key features of R-611 are summarized in Table 1. R-611 was reconstituted upon
transfection of BAC-611 DNA in CHO-EGFR cells and grown in RS or SK-OV-3 cells. The tropism
of the two batches was identical, ruling out that growth in one or the other of the two cell lines
selected for a variant virus. We interpret the infection and growth in RS as possibly mediated by a
rabbit ortholog of human EGFR. The results of the tropism assay in Figure 4C,D show that R-611
infected J-EGFR cells (Figure 4C, panel a; Figure 4D, panel a; 90.5% by flow cytometry) and infected
J-nectin1 cells at background levels (Figure 4C, panel d; Figure 4D, panel b; 2.4% by flow cytometry).
The retargeting to EGFR was confirmed by the neutralization of J-EGFR cell infection by the humanized
monoclonal antibody cetuximab directed to EGFR (Figure 4E, panel b). R-611 replicated in J-EGFR
cells (Figure 4F) to yields higher than 106 PFU/mL, i.e., to yields similar to those achieved by the
PSMA-retargeted R-593 in the J-PSMA cells. The infection was dramatically reduced by cetuximab.
In contrast to R-593, R-611 replicated in J-nectin1 cells, at a level two orders of magnitude lower than
that in J-EGFR cells. Such replication was independent of nectin1, since it was also observed in the
parental receptor-negative J cells, and since, in both cells, it was reduced to background levels by
cetuximab, hinting that it occurred in part through an EGFR ortholog. In support of this possibility,
we observed a species non-specific reactivity of J and J-nectin1 cells to an MAb directed to human
EGFR (Figure 1F,G). R-LM5 replicated to a background level in J-EGFR cells, and to very high yields in
J-nectin1 cells. Cytotoxicity assays mirrored the infection pattern. Thus, R-611 efficiently killed J-EGFR
but not J-nectin1 cells. Conversely, HSV-1(F) substantially spared J-EGFR cells, and was cytotoxic to
J-nectin1 cells, as expected (Figure 4G). R-611 infected human EGFR-positive cancer cells (Figure 4H,I).
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Often, human cancer cells express different members of the EGFR family in varying combinations and
degrees. This situation is exemplified by MDA-MB-231 and SK-OV-3 cells. The former express EGFR
and low level HER2 [71]; the second express EGFR and a substantial level of HER2 [70]. Both cell lines
enabled the replication of R-611 (Figure 4H). In addition the SK-OV-3 cells enabled the replication
of the HER2-retargeted R-LM113, which replicated to background levels in MDA-MB-231. The data
indicate that the aa 6–38 deletion in gD was suitable for engineering an scFv to EGFR, and enabled
the generation of a viable EGFR-retargeted recombinant. Given the apparent wide distribution of
EGFR in cancer and non-cancer cells, and its cross-specificity, the level of cancer-specificity that may
be achieved through this receptor needs to be critically evaluated.
3.5. The Insertion of the scFvs to PSMA, EGFRvIII, or EGFR in the Backbone of R-LM249 Failed to Generate
Viable Recombinants
The above viable recombinants R-593, R-613, and R-611 carried the appropriate scFvs in gD, in place of
aa 6–38 [27]. As mentioned, the deletion of aa 6–38 ablates targeting and binding to the natural gD receptors
HVEM and nectin1 [27]. R-LM249 carries the deletion of amino acids 61–218 in gD, and its replacement with
the scFv to HER2 [28]. Here, we engineered the scFv to PSMA, EGFRvIII, or EGFR in place of aa 61–218,
thus generating BAC-591, BAC-623, and BAC-621, respectively (Figure 5A,B). When transfected into target
cell lines expressing the cognate receptor, the recombinant BAC genomes did not give rise to viable viruses
(Figure 5C, panels a, c, e), but only to single EGFP-positive cells. To check whether the recombinant BAC
genomes carried defects in genes other than gD, they were transfected in R6 cells, which express wt gD
under the UL26.5 promoter [43]. The wt-gD transgenically expressed from these cells provides wt-gD in
trans, and can pseudotype virions. The results in Figure 5C (panels b, d, f) show that BAC-591, BAC-623,
and BAC-621 formed plaques in R6 cells, indicating that there was no defect in their genomes, except the
engineered modifications in the gD locus. The pseudotyped viruses were then employed to infect the
receptor-positive cognate cells. The recombinants failed to replicate and were lost after the first passage in
the respective receptor-positive tumor cells. We interpret the inability of the recombinants generated on the
backbone of ∆61–218 gD to grow in the respective target cells as possibly due to substantial alterations in
the recombinant gD, leading to loss of function. A non-mutually exclusive possibility is that the constraints
exerted by the gD structure may modify the scFv structure, and thus prevent its ability to interact with the
cognate receptor. These three recombinants could not be investigated further.
3.6. R-291 Carries Mutations in gB Which Increase the Spread in Murine Cells
R-LM249 exhibited a strong in vivo efficacy in immunodeficient mice xenografted with human
tumor cells expressing HER2 [28,34]. However, R-LM249 spread poorly in murine cells, thus hampering
efforts to evaluate its efficacy in immunocompetent murine models. The D285N and A549T substitutions
in HSV gB were described as “hyperactive mutations” capable of increasing HSV-1 cell-to-cell spread
and rate-of-entry [59]. A boosted cell-to-cell spread in murine cells would translate into an enhanced
efficiency of the oncolytic treatment in an immunocompetent mouse model, where only syngeneic
murine cancer cells can be implanted. In addition, mutations which affect the viral rate of entry could
increase infectivity and replication in human cells. In order to obtain an HER2-retargeted recombinant
more efficient in terms of the infection of murine cancer cells, and, possibly, of human cells, the two gB
mutations were inserted in R-LM249 (Figure 6A), thus generating R-291.The linear maps of R-291 gD
and gB are shown in Figure 6B. The replication of R-291 in human cancer cell lines, positive or negative
for HER2 expression, was compared to that of its parental R-LM249. R-LM5 (wt gD) was included for
comparison. Figure 6C shows that R-291 did not exhibit an increase in replication in the HER2-positive
SK-OV-3 cells, as compared to R-LM249. R-291 maintained the specific tropism for HER2-positive cells
and failed to substantially replicate in the HER2-negative Rh4 cells, similarly to its parent R-LM249.
Accordingly, the cytotoxic activities exerted by R-291 and its parent virus R-LM249 for the human
SK-OV-3 and Rh4 cells were undistinguishable (Figure 6D). The results on Rh4 cells rule out that the
mutations in gB conferred an off-target tropism.
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Figure 3. Properties of the EGFRvIII-retargeted R-613. (A) Schematic drawing of the R-613 genome.
The scFv to EGFRvIII is i serted in place of aa 6–38 of gD. pBeloBAC11 and EGFP (BAC EGFP) are
inserted between UL3 and UL4 [50]. (B) Linear maps of R-613 gD and of wt gD. The aa coordinates
relevant to this study are indicated. The two linear maps are drawn to scale. Scale bar, 50 amino acid
residues. L3, link r 3. (C) U251-EGFRvIII or U251 cell line were infected with the indicated viruses at
10 PFU/cell, or mock-infected. Pictures were taken at 24 h p.i. The levels, brightness, and contrast of
the panels were adjusted by means of Adobe Photoshop as follows: input level (black) 30, brightness
+60, contrast +60, scale bar =100 µm. (D) U251-EGFRvIII or U251 cells exposed to 10 PFU/cell of
R-613 or R-LM5, or mock infected (black line), were analyzed 24 h after infection by flow cytometry
for EGFP. The figures next to each virus name indicate the percentage of infection. Vertical red line:
threshold discriminating the negative and positive populations, as determined by comparison with the
negative control. (E) R-613 replication in U251-EGFRvIII cells infected at 0.1 PFU/cell and harvested
24, 48, and 72 h after infection. The data represent the average of three independent experiments ±
SD. (F,G) Effect of virus infection on cell viability. U251-EGFRvIII (F) and U251 (G) cells were infected
at 2.5 PFU/cell. Viability was quantified at the indicated days after infection. The data represent
the average of four replicate samples ± SD. (H) R-613 infection of the human glioma initiating cells
hGic-G15 (a, b), but not of hGic-G7 (c, d). Scale bar = 100 µm. Figures next to panels b and d indicate
the extent of infection as detected by cytofluorimetric analysis. Vertical red line: threshold between
negative and positive populations.
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Figure 4. Properties of EGFR-retargeted R-611. (A) Schematic drawing of the R-611 genome. The scFv to
EGFR was inserted in place of aa 6–38 of gD. pBeloBAC11 and EGFP (BAC EGFP) are inserted between
UL3 and UL4 [50]. (B) Linear map of wt gD and of recombinant gD in R-611. L3, linker 3. (C) J-EGFR
and J-nectin1 cells were infected with the indicated viruses at 10 PFU/cell. Pictures were taken at 24 h
after infection. The controls in J-nectin1 cells (R-LM5 and Mock) were the same as shown in Figure 2C,
since the experiments with different recombinant o-HSVs were run in parallel to facilitate comparison.
The levels, brightness, and contrast of the panels were adjusted by means of Adobe Photoshop as
follows: input level (black) 30, brightness +60, contrast +60, scale bar = 100 µm. (D) J-EGFR and
J-nectin1 cells exposed to 10 PFU/cell of R-611 or R-LM5, or mock infected (black line), were analyzed
by flow cytometry for EGFP fluorescence. The controls in J-nectin1 cells (R-LM5 and Mock) are the
same as in Figure 2D. The figures next to each virus name denote the percentage of infection. Vertical
red line: threshold discriminating the negative and positive populations, as determined by comparison
with the negative control. (E) Neutralization of R-611 infection in J-EGFR cells by the humanized
monoclonal antibody cetuximab directed to EGFR (83 µg/mL, panel b) or no antibody (no Ab) as
control (panel a). Pictures were taken at 24 h after infection. Scale bar = 100 µm. (F) R-611 replication
in J-EGFR, J-nectin1, and J cells, infected at 1 PFU/cell, in the absence or presence of cetuximab (Cet),
and harvested at the indicated times. The data represent the average of three independent experiments
± SD. R-LM5 replication in J-EGFR and J-nectin1 cells, infected at 1 PFU/cell. The data represent the
average of four independent experiments ± SD. (G) Effect of virus infection on cell viability. J-EGFR
(solid lines) or J-nectin1 (dashed lines) cells were infected at 5 PFU/cell with the indicated viruses.
The data represent the average of four replicate samples ± SD. (H) R-611 replication in EGFR-positive
MDA-MB-231 and SK-OV-3 tumor cells infected with at 1 PFU/cell and harvested at 24 and 48 h.
Bars represent the average of two independent experiments ± SD. (I) Infection of MDA-MB-231 cells
was documented by fluorescence microscopy (panel a) and quantified by flow cytometry (panel b).
Scale bar = 100 µm. Vertical red line: threshold between negative and positive populations.
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Figure 5. Failure to generate replication-competent recombinants by insertion of scFv in gD ∆61–218.
(A) Schematic drawing of the recombinant g nomes that carry the scFv in place of aa 61–218 of mature
gD. pBeloBAC11 and EGFP (BAC EGFP) are inserted between UL3 and UL4 [50]. (B) Schematic linear
maps of gD in recombinant BAC-591, BAC-623, and BAC-621 compared to wt gD. The aa coordinates
relevant to this study are indicated. Scale bar, 50 amino acid residues. L1, L2, linker 1 and 2. (C) The
recombinant genomes BAC-591, BAC-623, and BAC-621 carry non-functional recombinant gDs, and do
not carry defects in genes other than gD. Transfection of BAC DNAs in R6 cells expressing wt-gD under
the UL26.5 promoter allows the formation of plaques (panels b, d, f). Transfection of J cells expressing
the individual target receptor only gives rise to single EGFP-positive cells (panels a, c, e). Pictures were
taken at day 3 post transfection. The levels, brightness, and contrast of the panels were adjusted by
means of Adobe Photoshop as follows: brightness +120, input level (black) 30, then again brightness
+50, contrast +50. Scale bar = 100 µm.
To verify whether the gB mutations conferred an enhance infection in murin cancer cells,
we qu ntified the average plaque size in a murine cancer cell line stably expressing huma HER2
(B16-HER2). Figure 6E, panel b, shows that R-291 form d plaques in B16-HER2 cells, whereas the
parent R-LM249 (panel d) and the wt R-LM5 (panel f) only induced singly infected cells. Quantification
of the plaque size is reported in Figure 6F. It can be seen that the average plaque size by R-291 in
B16-HER2 cells was similar to that reached by R-LM249 in SK-OV-3 cells. Furthermore, the R-291
plaques were similar in size in SK-OV-3 and in B16-HER2 cells. The cell viability assay confirmed that
B16-HER2 cells were targeted by R-291, and to a lesser extent by R-LM249 (due to the lack of efficient
cell to cell spread), but not by R-LM5. Altogether, the gB mutations improved cell to cell spread among
murine an r cell , but not among th human SK-OV-3 cancer ells. This property may facilitate the
analysis of in vivo an itumor efficacy in immunoc mpetent mice implanted with syngeneic murine
cancer cells.
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Schematic diagram of wt gD (upper line), of R-LM249 and R-291 gD (middle line), and of R-291 gB 
(bottom line) carrying the mutations D285N and A549T (gBmut). (C) Replication of R-291, R-LM249, 
and R-LM5 recombinants in human HER2-positive (SK-OV-3) or HER2-negative (Rh4) tumor cell 
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(A) Schematic drawing of the R-291 genome. The scFv to HER2 is inserted in place of aa 61–218 of
gD. pBeloBAC11 and EGFP (BAC EGFP) ar inserted between UL3 and UL4 [50]. UL27, encoding gB,
is shown as a light blue box. gBmut carries the mutations D285N and A549T, as detailed in panel B.
(B) Schematic diagram of wt gD (upper line), of R-LM249 and R-291 gD (middle line), and of R-291 gB
(bottom line) carrying the mutations D285N and A549T (gBmut). (C) Replication of R-291, R-LM249,
and R-LM5 recombinants in human HER2-positive (SK-OV-3) or HER2-negative (Rh4) tumor cell lines,
infected at 1 PFU/cell, and harvested at 24 and 48 h after infection. The plotted values represent the
average of two independent experiments ± SD. (D) Effect of virus infection on cell viability. The human
HER2-positive (SK-OV-3) or HER2-negative (Rh4) tumor cell lines were infected at the indicated MOI
and cell viability was assessed at day 4. The bars represent the averages of at least three replicate
samples ± SD. (E) Examples of typical plaques by R-291, R-LM249, and R-LM5 in the B16 murine cell
line expressing HER2 (B16-HER2), and in SK-OV-3 cells. The levels, brightness, and contrast of the
panels were adjusted by means of Adobe Photoshop as follows: (a): input level (black) 30, brightness
+50, contrast +50; (b): brightness +50, contrast +80, input level (black) 50; (c) input level (black) 30,
brightness +50, contrast +50; (d): input level (black) 30, brightness +50, contrast +50; (e) input level
(black) 30, brightness +50, contrast +50; (f) input level (black) 30, brightness +100, contrast +50. Scale
bar = 100 µm. (F) Average sizes of plaques made by the indicated viruses in B16-HER2, and in the
human SK-OV-3 cells, for comparison. The bars represent the average pixel counts for 35 plaques ±
SD, in pictures taken with a 4× objective. *: statistically significant; n.s.: not significant. (G) Effect of
virus infection on B16-HER2 viability. Cells were infected at the indicated MOI and cell viability was
assessed at day 4. The bars represent the averages of four replicate samples ± SD.
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3.7. A Novel Insertion Site for Expression of the Heterologous mIL12 Gene
The next aim was to identify an additional insertion site in the HSV genome suitable for the
expression of a heterologous gene.
The known sites in the HSV genome suitable for the insertion of functional transgenes and capable
of giving rise to viable recombinants are limited in number. Here, we engineered a cassette for the
expression of murine interleukin 12 (mIL12) under the control of pCMV in the US1-US2 intergenic
locus of the HER2-retargeted R-LM113, thus generating R-115 (schematic drawing of R-115 genotype
in Figure 7A). IL12 is a potent immunostimulatory cytokine, capable of helping to break the tolerance
to tumors and induce an immunotherapeutic response [72]. Its systemic administration is marred
by toxicity, which can be overcome by loco-regional administration of the cytokine, e.g., by local
administration via a viral vector encoding the IL12 gene [73–80]. The rationale for choosing the
US1-US2 intergenic locus as the insertion site was as follows. US1-US2 genes are located on opposite
strands, but do not overlap, and are separated by an intergenic non coding region containing the two
convergent polyA signals and a 62-bp intergenic region (Figure 7B). Previously, this site was described
by Cunningham and Davison (GenBank: FJ593289.1) as a site where self-excising BAC sequences were
successfully inserted in the DNA of HSV-1 (strain 17). In that example, following the reconstitution of
the virus in cell culture, the heterologous sequences were removed. Hence, so far, it was unknown
whether this insertion site is suitable for the generation of viable recombinants, for the expression of
the inserted gene, and for stable expression. The insertion by Cunningham and Davison was placed
immediately downstream of the stop codon of the US1 open reading frame (coordinate 133910 in HSV-1
strain 17, GenBank # NC_001806.2). The insertion separated US1 ORF from its polyA signal sequences
(Figure 7B). Different from that construct, in our construct, the mIL12 cassette was engineered at
coordinate 133854 (coordinate of HSV-1(F) in GenBank # GU734771.1), i.e., in the central part of the
62-bp intergenic region (133823–133884) (see, schematic drawing in Figure 7B). This insertion preserved
the polyA signals for both US1 and US2. Figure 7C–E show that R-115 maintained the same tropism
exhibited by its parent R-LM113. As expected, R-115 did not substantially replicate in J-nectin1 cells
and replicated to similar titers as R-LM113 in J-HER2 cells (Figure 7E).
To ascertain whether mIL12 was indeed secreted by the infected cells, the medium of SK-OV-3
and J-HER2 cells was harvested 24 h after infection with R-115 (0.1 and 1 PFU/cell). mIL12 was
quantified by ELISA, using recombinant mIL12 as standard. The monoclonal employed for mIL12
determination reacted to the C-terminal p35 subunit, and thus ensured recognition of the mIL12 dimer.
Figure 7F shows that mIL12 was secreted in the medium of R-115-infected SK-OV-3 and J-HER2 cells,
and reached concentrations ranging between 100 and 400 pg/105 cells in the two cell lines at 24 h
after infection.
Altogether, the US1-US2 insertion site led to a recombinant capable of expressing the mIL12 transgene.
3.8. Detection of Viral Replication through Expression of the Gaussia Luciferase (GLuc) Reporter
The aim of the next series of experiments was to evaluate whether HSV replication can be monitored
through the expression of a recently described reporter, Gaussia Luciferase (GLuc), which can be detected
both in culture and in vivo. We engineered two recombinants. The first was R-613GLuc, a derivative
of R-613, which carries the GLuc gene in the UL37-UL38 intergenic region (see Figure 8A for genomic
organization). The second was R-615GLuc, which simultaneously expresses two transgenes. Preliminarily,
we generated R-615, which carries the mIL12 gene in the US1-US2 intergenic region (Figure 8B for
genomic organization), and under this respect is therefore similar to R-115. Subsequently, we inserted
the GLuc gene in the UL37-UL38 region of R-615, thus generating R-615GLuc (Figure 8C). See Table 1
for summary properties of the recombinants. Figure 8D,F show that the tropism of R-613GLuc, R-615,
and R-615GLuc was undistinguishable from that of the parental R-613 (Figure 3C,D). The replication of
R-615 and R-615GLuc was somewhat lower than that of R-613 and R-613GLuc (Figure 7G). mIL12 was
secreted in the medium of U251-EGFRvIII cells infected with R-615 and R-615GLuc, and at 1 PFU/cell
reached overall similar concentrations to those achieved by R-115 in J-HER2 and SK-OV-3 cells (compare
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Figure 8H with Figure 7F). The recombinants from this family could not be differentiated from each other
with respect to the ability to cause cytotoxicity in U251-EGFRvIII cells (Figure 8I).
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R-115. The scFv to HER2 is in gD, in place of aa 6–38; pBeloBAC11 and EGFP (BAC EGFP) are inserted
between UL3 and UL4 [50]; the mIL12 cassette was cloned between US1 and US2. (B) Details of the
US1-US2 intergenic region. PolyA addition sites are depicted as triangles. The coordinate for HSV-1(F)
(GenBank: GU734771.1) and HSV-1 strain 17 (NCBI RefSeq: NC_001806.2) are above and below the
diagram of the genes, spectiv ly. The coordi ates in red a d blue indicate the site of insertion used in
this study and by Davison et al. (GenBank: FJ593289.1), respectively. (C) J-HER2 or J-nectin1 cells were
infected with the indicated viruses at 10 PFU/cell. Pictur s were taken t 24 h p.i. The pictures relative
to the controls (R-LM5 and Mock in J-nectin1) are the same as shown in Figure 2C and 4C, since the
experiments were run in parallel. The levels, brightness, and contrast of the panels were adjusted by
means of Adobe Photoshop as follows: input level (black) 30, brightness +60, contrast +60. Scale bar =
100 µm. (D) J-HER2 or J-nectin1 cells infected as in panel C and analyzed by flow cytometry for EGFP
detection. The controls R-LM5 and Mock (black line) in J-nectin1 were presented in Figure 2D and 4D,
as the experiments were run in parallel. The figures next to each virus name indicate the percentage
of infected cells. Vertical red line: threshold discriminating the negative and positive populations,
as determined by comparison with the negative control. (E) R-115 replication in J-HER2 and J-nectin1
cells, infected at 0.1 PFU/cell and harvested at 24 and 48 h after infection. Histograms represent the
average of three independent experiments ± SD. (F) Quantification of mIL12 secreted in the media of
R-115-infected SK-OV-3 or J-HER2 cells, 24 h after infection at 0.1 and 1 PFU/cell. The bars represent
the averages of triplicates ± SD.
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Importantly, Figure 9A,B show that GLuc was secreted from cells infected with R-613GLuc and
R-615GLuc. The amount of secreted GLuc paralleled the increase in viral replication.
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Figure 9. Secretion of GLuc parallels virus replication. Expression of Gaussia Luciferase in
U251-EGFRvIII cells infected with R-613GLuc (A) or R-615GLuc (B) at MOI ranging from 0.01 to
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4. Discussion
The next generation oncolytic viruses will likely combine multiple genetic modifications to
make the viruses more potent and more cancer-specific, and to achieve the expression of transgenes.
In particular, genetic alterations are being designed that act synergistically to target tumors through
multiple mechanisms. A strategy towards more potent and more cancer-specific oncolytic viruses is
the retargeting of the viral tropism to cancer specific receptors.
In earlier work, we generated two HSV recombinants retargeted to the HER2 tumor cell specific
receptor, named R-LM113 and R-LM249. Both are non-attenuated, retargeted to HER2, and detargeted
from the natural HSV receptors HVEM and nectin1 [27,28]. Molecularly, the two viruses differ in
the gD sequences which were deleted for detargeting purposes, aa 6–38 or aa 61–218 in R-LM113 or
R-LM249, respectively. In both viruses, the deleted sequences were replaced with the scFv to HER2 for
retargeting purposes. No other genetic modification, including attenuation, was introduced. Hence,
they are fully virulent in their target cells. Here, we report that the ∆6–38 deletion in gD (R-LM113
backbone), but not the ∆61–218 deletion in gD (R-LM249 backbone), serves as a platform to engineer
HSVs retargeted to the PSMA, EGFRvIII, or EGFR tumor cell specific receptors. We identified a site
for transgene insertion which was not verified before for ability to drive the expression of the mIL12
transgene. This transgene was simultaneously expressed with the Gaussia Luciferase reporter. We
also found that mutations in gB, known to affect the HSV rate of entry, enhance the HER2-retargeted
o-HSV infection and cell to cell spread in murine cells.
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4.1. Platform to Engineer Novel Retargeted HSVs
The insertion of the specific scFvs in ∆6–38 gD (R-LM113 backbone) resulted in HSV
recombinants retargeted to PSMA, EGFRvIII, and EGFR, and detargeted from the natural gD receptors.
The recombinants efficiently spread from cell to cell, grew to high titers, and were cytotoxic to cells.
Of note was the EGFR-retargeted R-611, which additionally replicated, albeit to a lower extent, in the
receptor-negative J cells, as well as in J-nectin1 cells. The latter two infections were inhibited by
the anti-EGFR cetuximab, hinting that they occurred through a hamster EGFR ortholog present in J
cells. This interpretation is consistent with the finding that R-611 can be grown in RS cells as well.
Cumulatively, the current results on R-611 are not in contrast with the conclusions that R-611 is
retargeted to EGFR and detargeted from nectin1/HVEM. Rather, they call for a careful evaluation
when considering EGFR as a specific objective for targeted therapy. The results with the scFv insertion
in the ∆6–38 gD contrast with those obtained with insertion in the ∆61–218 gD (R-LM249 backbone).
In the latter case, no viable recombinant could be generated, unless they were pseudotyped with wt
gD. Thus, the failure to form infectious virions in the R-LM249 backbone mapped to gD. In conclusion,
of four scFvs tested, only the one to HER2 was capable of generating viable recombinants when
inserted in the ∆61–218 gD. We note that the scFv to HER2 has the composition VL-linker-VH, whereas
the scFvs to PSMA, EGFRvIII, and EGFR employed in this study had the composition VH-linker-VL.
We also note that when the scFvs were inserted in the ∆6–38 gD (R-LM113 backbone), they were
located at the very N-terminus of the chimeric molecule, and most likely were free to adopt their
conformation, to position themselves relative to the rest of gD, and let gD do its gymnastics. In contrast,
when the scFvs were inserted in the ∆61–218 gD, they replaced the core of the molecule. It is possible
that their own conformation was constrained, and/or that the remaining portions of gD, including the
profusion domain, were distorted, or were not able to adopt the proper conformation and to carry out
the gymnastics required of gD to activate gH and gB.
Importantly, the three recombinants generated in this study were all able to infect human cancer
cells expressing the targeted receptors, i.e., PSMA, EGFRvIII, or EGFR. Thus, the level of expression of
these receptors in bona fide human cancer cells is suitable to enable infection with the retargeted o-HSVs.
4.2. Effects of Mutations in gB on Cell-to Cell Spread of Retargeted o-HSVs
The D285N and A549T substitutions in HSV gB described earlier as “hyperactive mutations” [59]
conferred to an HER2-retargeted o-HSV an enhanced cell-to-cell spread in B16-HER2 murine cancer
cells. Of note, B16 cells are scarcely susceptible to HSV carrying wt gD [63,81]. The boosted cell-to-cell
spread in murine cell lines may allow and facilitate the analysis of in vivo antitumor efficacy in
immunocompetent mice, which can only accept syngeneic cancer cells. Given that the R-291 tropism
to the natural HSV receptors was ablated and the mutations in gB did not enhance the ability of R-291
to spread among HER-2 positive cells, we consider it unlikely that in humans, the gB mutations would
expand infection to non-tumor cells.
4.3. Functional Insertion of Transgenes in HSV Genome
O-HSVs induce anti-tumor immunity and can be armed with therapeutic transgenes. Indeed, one
of the keys to success for the oncolytic HSV OncovexGM-CSF (T-VEC) was most likely the expression
of the GM-CSF transgene. In addition to the insertion of IL12 or GM-CSF, additional cytokines,
e.g., IL15; chemokines, e.g., CXCL10; or positive regulators of the immune response, e.g., ligands of
co-stimulatory receptors, are being actively investigated [76,82–86]. Expressing them from the viral
genome might favor high intratumoral concentrations of the transgenic molecules, and avoid toxicities
consequent to systemic delivery. It has thus become crucial to identify additional sites of insertion in the
HSV genomes. To our knowledge, sites of insertion which lead to functional transgenic molecules and,
at the same time, to viable HSVs capable of strong replication are the intergenic regions between UL3
and UL4 [50], between UL26 and UL27 [87], and between UL37 and UL38 [88]. The intergenic region
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between US1 and US2 (two non-essential genes in cell culture) was first described in GenBank entry
FJ593289.1 (Cunningham and Davison) as a site where self-excising BAC sequences were successfully
inserted. In that example, following the reconstitution of the virus in cell culture, the heterologous
sequences were removed. Therefore, the effect of insertion at this site on viral replication was not
known. At this locus, we inserted mIL12. The resulting recombinants R-115 and R-615 were viable,
replicated to high titers, and, to our knowledge, were genetically stable.
The second transgene was the Gaussia Luciferase (GLuc). This reporter was of interest because it is
secreted from the cells and its luminescence activity can be measured in extracellular fluids, cell culture
medium, or blood, by directly supplying the substrate, without any purification. Quantification of
GLuc activity in the blood makes it possible to evaluate virus replication (or alternatively tumor growth)
in whole animals by a non-invasive assay [89,90]. In cultured cells infected with two GLuc-expressing
recombinants, R-613GLuc and R-615GLuc, the amount of secreted GLuc paralleled the increase in viral
replication. It was not possible to unequivocally associate the GLuc level with the viral titer; however, a
time-course measurement of GLuc holds promise to be a reliable tool for monitoring viral replication in
in vivo experimental settings. The extent of G-Luc expression achieved with R-613GLuc and R-615Gluc
(108 relative luciferase units) is much higher than that reported for murine cytomegalovirus (104 relative
luciferase units) at an equivalent MOI [90]; the latter virus enabled the evaluation of virus replication in
mice in situ and in the blood. Thus, the extent of GLuc expression achieved with the retargeted o-HSVs
described here will likely enable the evaluation of virus growth in mice.
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